Eris Lifesciences

India's Shift To Branded Generics Will Expand Chronic Therapy Markets

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

19 Mar 25

Updated

18 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

6.4%

7D

-2.7%

Loading

1Y

6.4%

7D

-2.7%

You can edit this narrative until Nov 19 8:05 PM. Then, changes will post as Updates.

Author's Valuation

₹1.81k14.1% undervalued

AnalystConsensusTarget Fair Value

Shared on 18 Nov 25

Fair value Decreased 2.85%

ERIS: Approval From Brazil's ANVISA Will Drive Future Market Expansion

Analysts have slightly lowered their price target for Eris Lifesciences from ₹1,860.10 to ₹1,807.10. They cite minor adjustments to growth projections and profitability estimates as the reason for this change.

Shared on 07 Aug 25

Fair value Increased 8.97%

The consensus price target for Eris Lifesciences has been raised to ₹1852, reflecting improved expectations for both revenue growth and net profit margin. What's in the News Board meeting scheduled to approve standalone and consolidated unaudited financial results for the quarter ended June 30, 2025.

Shared on 01 May 25

Fair value Increased 6.66%

Shared on 24 Apr 25

Fair value Decreased 6.25%

AnalystConsensusTarget has increased shares outstanding growth rate from -0.0% to -0.0%.

Shared on 17 Apr 25

Fair value Increased 6.51%

Shared on 09 Apr 25

Fair value Increased 1.11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 5.69%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget Fair Value

₹1.81k

14.1% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

14.76%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

12.76%

Calculation

₹10.74b

Earnings '28

x

33.05x

PE Ratio '28

=

₹354.93b

Market Cap '28

₹354.93b

Market Cap '28

/

137.13m

No. shares '28

=

₹2.59k

Share Price '28

₹2.59k Share Price '28

Discounted to 2025 @ 12.76% p.a.

=

₹1.81k

Fair Value '25